<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05098509</url>
  </required_header>
  <id_info>
    <org_study_id>SCOUT-015</org_study_id>
    <nct_id>NCT05098509</nct_id>
  </id_info>
  <brief_title>A Phase 2/3 Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients With Prader-Willi Syndrome</brief_title>
  <acronym>SCOUT-015</acronym>
  <official_title>A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients With Prader- Willi Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radius Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radius Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a seamless Phase 2/3, double-blind, randomized, placebo-controlled clinical study in&#xD;
      patients diagnosed with PWS. Following consent (or legal guardian consent and patient assent&#xD;
      as appropriate), patients will be screened for eligibility to participate in this study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 3, 2022</start_date>
  <completion_date type="Anticipated">August 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2024</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HQ-CT Questionnaire</measure>
    <time_frame>Baseline through Week 34</time_frame>
    <description>The primary objective of the Phase 3 part of this study is to assess the effect of RAD011 on hyperphagia related behavior in patients with Prader-Willi Syndrome. This is a FDA recommended fully validated 9 question scale, with scores from 0 to 36, where the higher the score, the worse the condition.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aberrant Behavior Checklist - Irritability</measure>
    <time_frame>Baseline through Week 34</time_frame>
    <description>Effect of RAD011 on irritability subscale change in ABC-I score. Scores range 0 through 45, where the higher the score, the worse the condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Clinical Global Impression of Change - Severity Scale (CGI-S)</measure>
    <time_frame>Baseline through Week 34</time_frame>
    <description>Effect of RAD011 on Physician Clinical Global Impression of Change - Severity Scale. Scores range from 0 to 7, with 7 being &quot;among the most extremely ill patients&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aberrant Behavior Checklist</measure>
    <time_frame>Baseline through Week 34</time_frame>
    <description>Effect of RAD011 on overall behavior; the scores range 0 through 174, where the higher the score, the worse the condition.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety</measure>
    <time_frame>Baseline through Week 38</time_frame>
    <description>Treatment-emergent adverse events in active Investigational Product versus placebo treatment arms</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Prader-Willi Syndrome</condition>
  <arm_group>
    <arm_group_label>RAD011 high dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>RAD011 medium dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>RAD011 low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RAD011</intervention_name>
    <description>Synthetic Cannabidiol Oral Solution</description>
    <arm_group_label>RAD011 high dose</arm_group_label>
    <arm_group_label>RAD011 low dose</arm_group_label>
    <arm_group_label>RAD011 medium dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females between 8 and 65 years of age (inclusive) at Screening&#xD;
&#xD;
          -  Genetically confirmed diagnosis of PWS. Documentation of genetically confirmed&#xD;
             diagnosis of PWS is acceptable.&#xD;
&#xD;
          -  The same caregiver is available to complete the questionnaire throughout the duration&#xD;
             of the study.&#xD;
&#xD;
          -  After completion of the Tolerability period, Patients will have a mean HQ-CT score &gt;=&#xD;
             13 and a decrease of HQ-CT score no more than 7 during Tolerability (run-in) period&#xD;
&#xD;
          -  If receiving Growth Hormone, psychotropic therapy, and other treatment including&#xD;
             thyroid hormone, must be on the same medication and dose for at least 6 weeks prior to&#xD;
             Screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known use of cannabis or cannabinoid containing products (including topical products)&#xD;
             within 4 weeks prior to screening&#xD;
&#xD;
          -  Use of prescription or over-the-counter weight loss agents or drugs known to affect&#xD;
             appetite (including glucagon like peptide 1 receptor agonist) within 2 months prior to&#xD;
             screening&#xD;
&#xD;
          -  Implementation of new food or environmental restrictions within one month of screening&#xD;
&#xD;
          -  Living in a group home setting 50% or more of the time&#xD;
&#xD;
          -  Uncontrolled chronic conditions (diabetes, sleep apnea, etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ellie Ratigan</last_name>
    <phone>617-444-1800</phone>
    <email>scout015@radiuspharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nick Poulson</last_name>
    <phone>617-444-1800</phone>
    <email>scout015@radiuspharm.com</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 22, 2021</study_first_submitted>
  <study_first_submitted_qc>October 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2021</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prader-Willi Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

